GF Fund Management’s Autolus Therapeutics AUTL Stock Holding History

GF Fund Management’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.65K	Sell	4,154 -319	-7%	-$500	﹤0.01%	560
2026 Q1	$6.17K	Buy	4,473 +532	+13%	+$808	﹤0.01%	593
2025 Q4	$7.84K	Sell	3,941 -320	-8%	-$492	﹤0.01%	599
2025 Q3	$6.95K	Sell	4,261 -852	-17%	-$1.66K	﹤0.01%	585
2025 Q2	$11.7K	Hold	5,113	–	–	﹤0.01%	553
2025 Q1	$7.92K	Buy	5,113 +920	+22%	+$1.87K	﹤0.01%	588
2024 Q4	$9.85K	Buy	+4,193	New	+$14.2K	﹤0.01%	545

Other funds holding AUTL

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GF Fund Management's AUTL Position: Q2 2026 in Review

GF Fund Management reduced its Autolus Therapeutics (AUTL) stake by 7.1% in Q2 2026, selling an estimated $500 and leaving 4,154 shares worth $6.65K. The position accounts for ﹤0.01% of the portfolio, ranked #560.

GF Fund Management first reported a position in AUTL in Q4 2024 and has held it in 7 quarters since. The position peaked at $11.7K in Q2 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

GF Fund Management held 4,154 shares of Autolus Therapeutics worth $6.65K as of Q2 2026.
GF Fund Management sold 319 Autolus Therapeutics shares in Q2 2026, an estimated $500.
Autolus Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #560 holding.
GF Fund Management first reported a position in Autolus Therapeutics in Q4 2024 and has held it in 7 quarters since.
GF Fund Management's Autolus Therapeutics position peaked at $11.7K in Q2 2025.
84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.